VSTM Stock - Verastem, Inc.
Unlock GoAI Insights for VSTM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $10.00M | N/A | $2.60M | $2.05M | $88.52M |
| Gross Profit | $10.00M | N/A | $2.60M | $2.05M | $54.77M |
| Gross Margin | 100.0% | N/A | 100.0% | 100.0% | 61.9% |
| Operating Income | $-114,956,000 | $-92,084,000 | $-72,937,000 | $-61,409,000 | $-49,360,000 |
| Net Income | $-130,637,000 | $-87,367,000 | $-73,812,000 | $-71,200,000 | $-67,726,000 |
| Net Margin | -1306.4% | N/A | -2843.3% | -3468.1% | -76.5% |
| EPS | $-3.66 | $-3.96 | $-4.57 | $-4.92 | $-5.28 |
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Visit WebsiteEarnings History & Surprises
VSTMEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 19, 2026 | $-0.45 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.51 | $-1.35 | -164.7% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-0.85 | $-0.39 | +54.1% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-0.72 | $-0.96 | -33.3% | ✗ MISS |
Q1 2025 | Mar 20, 2025 | $-0.81 | $-1.33 | -64.2% | ✗ MISS |
Q4 2024 | Nov 6, 2024 | $-0.71 | $-0.60 | +15.5% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-1.06 | $-0.31 | +70.8% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-1.16 | $-1.26 | -8.6% | ✗ MISS |
Q1 2024 | Mar 14, 2024 | $-0.82 | $-1.02 | -24.4% | ✗ MISS |
Q4 2023 | Nov 8, 2023 | $-0.92 | $-0.75 | +18.5% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-1.13 | $-1.37 | -21.2% | ✗ MISS |
Q2 2023 | May 9, 2023 | $-1.08 | $-0.96 | +11.1% | ✓ BEAT |
Q1 2023 | Mar 14, 2023 | $0.10 | $-0.96 | -1060.0% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $-1.44 | $-1.08 | +25.0% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-1.32 | $-1.44 | -9.1% | ✗ MISS |
Q2 2022 | May 9, 2022 | $-0.96 | $-1.08 | -12.5% | ✗ MISS |
Q1 2022 | Mar 28, 2022 | $-0.96 | $-1.08 | -12.5% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $-1.08 | $-1.56 | -44.4% | ✗ MISS |
Q3 2021 | Aug 2, 2021 | $-1.08 | $-1.20 | -11.1% | ✗ MISS |
Latest News
Frequently Asked Questions about VSTM
What is VSTM's current stock price?
What is the analyst price target for VSTM?
What sector is Verastem, Inc. in?
What is VSTM's market cap?
Does VSTM pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to VSTM for comparison